These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9650541)

  • 1. Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction.
    Keung AC; Eller MG; Weir SJ
    J Clin Pharmacol; 1998 Jun; 38(6):517-24. PubMed ID: 9650541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single and multiple dose pharmacokinetics of rifapentine in man: part II.
    Keung A; Eller MG; McKenzie KA; Weir SJ
    Int J Tuberc Lung Dis; 1999 May; 3(5):437-44. PubMed ID: 10331734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose pharmacokinetics of rifapentine in elderly men.
    Keung AC; Eller MG; Weir SJ
    Pharm Res; 1998 Aug; 15(8):1286-91. PubMed ID: 9706063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose pharmacokinetics of rifapentine in women.
    Keung AC; Eller MG; Weir SJ
    J Pharmacokinet Biopharm; 1998 Feb; 26(1):75-85. PubMed ID: 9773393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects.
    Winter H; Egizi E; Murray S; Erondu N; Ginsberg A; Rouse DJ; Severynse-Stevens D; Pauli E
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1219-24. PubMed ID: 25512422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study.
    Keung AC; Owens RC; Eller MG; Weir SJ; Nicolau DP; Nightingale CH
    Antimicrob Agents Chemother; 1999 May; 43(5):1230-3. PubMed ID: 10223941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I.
    Keung A; Reith K; Eller MG; McKenzie KA; Cheng L; Weir SJ
    Int J Tuberc Lung Dis; 1999 May; 3(5):426-36. PubMed ID: 10331733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
    Dooley K; Flexner C; Hackman J; Peloquin CA; Nuermberger E; Chaisson RE; Dorman SE
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4037-42. PubMed ID: 18765687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifapentine pharmacokinetics in adolescents.
    Marshall JD; Abdel-Rahman S; Johnson K; Kauffman RE; Kearns GL
    Pediatr Infect Dis J; 1999 Oct; 18(10):882-8. PubMed ID: 10530584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of rifapentine in children.
    Blake MJ; Abdel-Rahman SM; Jacobs RF; Lowery NK; Sterling TR; Kearns GL
    Pediatr Infect Dis J; 2006 May; 25(5):405-9. PubMed ID: 16645503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition and metabolism of 14C-rifapentine in healthy volunteers.
    Reith K; Keung A; Toren PC; Cheng L; Eller MG; Weir SJ
    Drug Metab Dispos; 1998 Aug; 26(8):732-8. PubMed ID: 9698286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
    Weiner M; Bock N; Peloquin CA; Burman WJ; Khan A; Vernon A; Zhao Z; Weis S; Sterling TR; Hayden K; Goldberg S;
    Am J Respir Crit Care Med; 2004 Jun; 169(11):1191-7. PubMed ID: 14962821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.
    Dooley KE; Savic RM; Park JG; Cramer Y; Hafner R; Hogg E; Janik J; Marzinke MA; Patterson K; Benson CA; Hovind L; Dorman SE; Haas DW;
    Antimicrob Agents Chemother; 2015; 59(6):3399-405. PubMed ID: 25824215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
    Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
    Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs.
    Dutta NK; Alsultan A; Peloquin CA; Karakousis PC
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1535-7. PubMed ID: 23295923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
    Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
    Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.
    Weiner M; Egelund EF; Engle M; Kiser M; Prihoda TJ; Gelfond JA; Mac Kenzie W; Peloquin CA
    J Antimicrob Chemother; 2014 Apr; 69(4):1079-85. PubMed ID: 24343893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q; Iyer GR; Verhaeghe T; Truyen L
    J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.
    Grasela DM; Christofalo B; Kollia GD; Duncan G; Noveck R; Manning JA; LaCreta FP
    Pharmacotherapy; 2000 Jun; 20(6 Pt 2):87S-94S. PubMed ID: 10850525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.
    Wang J; Wang X; Zhang ZY; Arora S; Lu S; Kansra V
    J Clin Pharmacol; 2018 May; 58(5):686-693. PubMed ID: 29329482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.